Literature DB >> 8634960

Direct and indirect costs of asthma in Canada, 1990.

M D Krahn1, C Berka, P Langlois, A S Detsky.   

Abstract

OBJECTIVE: To calculate the direct and indirect costs of asthma in Canada.
DESIGN: Cost-of-illness study.
SETTING: Canada. PATIENTS: All Canadians receiving inpatient or outpatient care for asthma in 1990. OUTCOME MEASURES: Direct costs incurred by inpatient care, emergency services, physician and nursing services, ambulance use, drugs and devices, outpatient diagnostic tests, research and education. Indirect costs from productivity loss due to absence from work, inability to to perform housekeeping activities, need to care for children with asthma who were absent from school, time spent travelling and waiting for medical care, and premature death from asthma. All costs are in 1990 Canadian dollars.
RESULTS: Depending on assumptions, the total cost of asthma was estimated to be between $504 million and $648 million. Direct costs were $306 million. The single largest component of direct costs was the cost of drugs ($124 million). The largest component of indirect costs was illness-related disability ($76 million).
CONCLUSIONS: Annual costs of treating asthma are comparable to the individual cost of infectious diseases, hematological diseases, congenital defects, perinatal illnesses, home care and ambulance services. Asthma costs may increase in the future, given current morbidity and mortality trends. Further evaluation of the effectiveness and cost-effectiveness of available asthma interventions in addition to aggregate cost data are required to determine whether resource allocation for the treatment of asthma can be improved.

Entities:  

Mesh:

Year:  1996        PMID: 8634960      PMCID: PMC1487808     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  50 in total

1.  Cost of illness studies: no aid to decision making: Reply to Shiell et al. (Health Policy, 8 (1987) 317-323).

Authors:  C Behrens; K Henke
Journal:  Health Policy       Date:  1988-10       Impact factor: 2.980

2.  Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323).

Authors:  T A Hodgson
Journal:  Health Policy       Date:  1989       Impact factor: 2.980

3.  Asthma, wheezing, and school absence in primary schools.

Authors:  R A Hill; P J Standen; A E Tattersfield
Journal:  Arch Dis Child       Date:  1989-02       Impact factor: 3.791

4.  The impact of health education on frequency and cost of health care use by low income children with asthma.

Authors:  N M Clark; C H Feldman; D Evans; M J Levison; Y Wasilewski; R B Mellins
Journal:  J Allergy Clin Immunol       Date:  1986-07       Impact factor: 10.793

5.  Philosophical origins of the economic valuation of life.

Authors:  J C Robinson
Journal:  Milbank Q       Date:  1986       Impact factor: 4.911

Review 6.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

7.  Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.

Authors:  F Fincker; R Sauvan; J Pasquier
Journal:  Am J Clin Oncol       Date:  1988       Impact factor: 2.339

8.  International trends in hospital admission rates for asthma.

Authors:  E A Mitchell
Journal:  Arch Dis Child       Date:  1985-04       Impact factor: 3.791

Review 9.  The role of patient education in the management of childhood asthma.

Authors:  S R Wilson-Pessano; W L McNabb
Journal:  Prev Med       Date:  1985-11       Impact factor: 4.018

10.  The economic costs of illness: a replication and update.

Authors:  D P Rice; T A Hodgson; A N Kopstein
Journal:  Health Care Financ Rev       Date:  1985
View more
  43 in total

1.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

2.  First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma.

Authors:  L Blais; S Suissa; J F Boivin; P Ernst
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

3.  Respiratory day hospital: a novel approach to acute respiratory care.

Authors:  K Schwartzman; G Duquette; M Zaoudé; M J Dion; M A Lagacé; J Poitras; M G Cosio
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

4.  Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma.

Authors:  A L Kozyrskyj; C A Mustard; M S Cheang; F E Simons
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 5.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

6.  Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma.

Authors:  S Suissa; P Ernst; A Kezouh
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

7.  Action plans in asthma.

Authors:  Marie-France Beauchesne; Valérie Levert; Miray El Tawil; Manon Labrecque; Lucie Blais
Journal:  Can Respir J       Date:  2006-09       Impact factor: 2.409

8.  Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study.

Authors:  P Aggarwal; S Sharad; R Handa; S N Dwiwedi; M Irshad
Journal:  Emerg Med J       Date:  2006-05       Impact factor: 2.740

9.  Factors associated with the appropriate use of asthma drugs.

Authors:  Marie-Sophie Jobin; Jocelyne Moisan; Yves Bolduc; Eileen Dorval; Louis-Philippe Boulet; Jean-Pierre Grégoire
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 10.  Towards Excellence in Asthma Management: final report of an eight-year program aimed at reducing care gaps in asthma management in Quebec.

Authors:  Louis-Philippe Boulet; E Dorval; M Labrecque; M Turgeon; T Montague; R L Thivierge
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.